Please use this identifier to cite or link to this item: https://doi.org/10.1155/2015/457123
DC FieldValue
dc.titleSafety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease
dc.contributor.authorYong, K.-L
dc.contributor.authorChng, C.L
dc.contributor.authorHtoon, H.M
dc.contributor.authorLim, L.H
dc.contributor.authorSeah, L.L
dc.date.accessioned2020-10-27T05:43:38Z
dc.date.available2020-10-27T05:43:38Z
dc.date.issued2015
dc.identifier.citationYong, K.-L, Chng, C.L, Htoon, H.M, Lim, L.H, Seah, L.L (2015). Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease. International Journal of Endocrinology 2015 : 457123. ScholarBank@NUS Repository. https://doi.org/10.1155/2015/457123
dc.identifier.issn16878337
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/180924
dc.description.abstractObjective. To analyze changes in vital signs (heart rate (HR), systolic (SBP), and diastolic blood pressure (DBP)) during and after intravenous methylprednisolone (IVMP) and any other adverse effects. Methods. Retrospective review of charts of patients who received IVMP as treatment regime for thyroid eye disease. All subjects had vital signs charted during and after infusions. Results. This study included 38 subjects and a total of 242 infusions administered. IVMP resulted in a small but significant percentage drop in mean SBP at 30 min (p < 0.001) and 60 min (p = 0.03) but no difference at 90 min. There was also small but significant percentage drop in mean DBP and HR (DBP: p < 0.001 for 30 min, p = 0.001 for 60 min, and p = 0.02 for 90 min and HR: p < 0.001 for 30 min, 60 min, and 90 min). There were no cumulative effects on change of blood pressure or HR. There were 6 episodes of bradycardia (2.5%) and 12 episodes of moderate to severe hypertension (5%). No significant cardiovascular or hepatic toxicity was found. Conclusion. IVMP is relatively safe and efficacious. IVMP demonstrated mild and noncumulative effects on vital signs. Severe hypertension may occur in susceptible individuals such as those with underlying hypertension and uncontrolled thyroid dysfunction, whereas bradycardia may be more likely in those on beta-blockers. © 2015 Kai-Ling Yong et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectglucose
dc.subjectliver enzyme
dc.subjectmethotrexate
dc.subjectmethylprednisolone
dc.subjectpotassium
dc.subjectadjuvant chemoradiotherapy
dc.subjectadjuvant therapy
dc.subjectadult
dc.subjectArticle
dc.subjectbradycardia
dc.subjectchest tightness
dc.subjectclinical article
dc.subjectcolor vision
dc.subjectcombination chemotherapy
dc.subjectcontrolled study
dc.subjectdecompression surgery
dc.subjectdiastolic blood pressure
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug pulse therapy
dc.subjectdrug safety
dc.subjectdyspnea
dc.subjectECG abnormality
dc.subjectendocrine ophthalmopathy
dc.subjectfemale
dc.subjectfever
dc.subjectflushing
dc.subjectgastritis
dc.subjectglucose blood level
dc.subjectheadache
dc.subjectheart palpitation
dc.subjectheart rate
dc.subjecthuman
dc.subjecthypertension
dc.subjecthyperthyroidism
dc.subjectinsomnia
dc.subjectmale
dc.subjectmonotherapy
dc.subjectmultiple cycle treatment
dc.subjectpotassium blood level
dc.subjectpriority journal
dc.subjectrash
dc.subjectretrospective study
dc.subjectside effect
dc.subjectslit lamp
dc.subjectsystolic blood pressure
dc.subjecttachycardia
dc.subjectthyroid function test
dc.subjecttreatment duration
dc.subjecttreatment indication
dc.subjecttreatment withdrawal
dc.subjecturticaria
dc.subjecturticarial rash
dc.subjectvisual acuity
dc.subjectvital sign
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.contributor.departmentDEPT OF OPHTHALMOLOGY
dc.description.doi10.1155/2015/457123
dc.description.sourcetitleInternational Journal of Endocrinology
dc.description.volume2015
dc.description.page457123
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2015_457123.pdf1.35 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Jun 21, 2022

Page view(s)

139
checked on Jun 23, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons